RxDoctor Payments Data

Graciela Maalouf, MD

Internal Medicine · Orlando, FLNPI 1992968028

Payments from drug & device makers

$1,049in general payments, 2019–2025

Across 26 payments — averaging $40.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$252
  • Novo Nordisk$161
  • Stryker$135
  • Mylan Specialty L.p.$119
  • Urovant Sciences Inc$102
  • Sunovion Pharmaceuticals Inc.$89
  • plus $190 from 7 others

What the payments were for

  • Food & beverage$1,049100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,049 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$242,555
Medicare patients
704
Services billed
2,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban881$294,867
AustedoDeutetrabenazine23$83,081
JardianceEmpagliflozin120$52,632
XareltoRivaroxaban144$43,029
NuedextaDextromethorphan Hbr/Quinidine53$41,080
GemtesaVibegron160$40,297
OzempicSemaglutide32$37,281
JanuviaSitagliptin Phosphate89$34,781
TrulicityDulaglutide63$32,342
RybelsusSemaglutide16$22,248
AptiomEslicarbazepine Acetate34$22,180
Atorvastatin Calcium1,251$20,979
Divalproex Sodium285$19,934
SecuadoAsenapine12$17,640
Memantine Hcl263$16,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$294,867881 claims
Novo NordiskOzempic, Rybelsus$161$59,52948 claims
Boehringer IngelheimJardiance, Tradjenta$24$59,182136 claims
Avanir Pharmaceuticals, Inc.Nuedexta$15$41,08053 claims
Sumitomo Pharma America, Inc.Gemtesa$42$40,297160 claims
Sunovion Pharmaceuticals Inc.Aptiom$89$22,18034 claims
AbbVieLinzess, Namzaric$252$21,25949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →